Endocrinology, Vol 129, 1915-1925, Copyright © 1991 by Endocrine Society

ARTICLES

Glucose transport deficiency in diabetic animals is corrected by treatment with the oral antihyperglycemic agent pioglitazone

C Hofmann, K Lorenz and JR Colca
Department of Biochemistry, Loyola University Stritch School of Medicine, Maywood, Illinois 60153.

Insulin-stimulated glucose uptake into muscle and fat involves regulation of the subcellular distribution and the expression of a specific facilitative glucose transporter protein (GLUT4). Peripheral glucose uptake is lowered in diabetes, and the expression of GLUT4 is depressed in animals that have been made diabetic (i.e. insulin deficient) by destruction of the pancreatic beta-cells. In the present study we found that GLUT4 expression is also decreased in an animal model for type II diabetes mellitus (noninsulin-dependent diabetes mellitus), KKAY obese mice. These KKAY mice have elevated circulating insulin levels, but target cell resistance to the metabolic actions of insulin. Treatment of both types of diabetic animals with pioglitazone, a new antihyperglycemic compound, corrects deficits in glucose transport and GLUT4 mRNA and protein abundance. Such corrections are, however, more readily detected in fat than in muscle. Increases in GLUT4 mRNA and protein levels and glucose transport function by pioglitazone are dependent upon the presence of circulating insulin. Treatment with pioglitazone alone is sufficient for correction of glucose transport in hyperinsulinemic insulin-resistant animals, but hypoinsulinemic animals require insulin therapy along with pioglitazone treatment for similar corrections. In these insulin-deficient animals, neither treatment with the drug alone nor minimal insulin replacement therapy results in substantial correction. Since insulin and this antihyperglycemic agent seem to work synergistically, it is likely that pioglitazone acts to amplify cellular responses to insulin.

This article has been cited by other articles:

				J. Takada, M. H. Fonseca-Alaniz, T. B. F. de Campos, S. Andreotti, A. B. Campana, M. Okamoto, C. d. N. Borges-Silva, U. F. Machado, and F. B. Lima Metabolic recovery of adipose tissue is associated with improvement in insulin resistance in a model of experimental diabetes J. Endocrinol., July 1, 2008; 198(1): 51 - 60. [Abstract] [Full Text] [PDF]

				K. T. Dalen, S. M. Ulven, K. Bamberg, J.-A. Gustafsson, and H. I. Nebb Expression of the Insulin-responsive Glucose Transporter GLUT4 in Adipocytes Is Dependent on Liver X Receptor {alpha} J. Biol. Chem., November 28, 2003; 278(48): 48283 - 48291. [Abstract] [Full Text] [PDF]

				M. D. Aleo, G. R. Lundeen, D. K. Blackwell, W. M. Smith, G. L. Coleman, S. W. Stadnicki, and W. M. Kluwe Mechanism and Implications of Brown Adipose Tissue Proliferation in Rats and Monkeys Treated with the Thiazolidinedione Darglitazone, a Potent Peroxisome Proliferator-Activated Receptor-{gamma} Agonist J. Pharmacol. Exp. Ther., June 1, 2003; 305(3): 1173 - 1182. [Abstract] [Full Text] [PDF]

				S. R. Keller, A. C. Davis, and K. B. Clairmont Mice Deficient in the Insulin-regulated Membrane Aminopeptidase Show Substantial Decreases in Glucose Transporter GLUT4 Levels but Maintain Normal Glucose Homeostasis J. Biol. Chem., May 10, 2002; 277(20): 17677 - 17686. [Abstract] [Full Text] [PDF]

				M. Shintani, H. Nishimura, S. Yonemitsu, Y. Ogawa, T. Hayashi, K. Hosoda, G. Inoue, and K. Nakao Troglitazone Not Only Increases GLUT4 but Also Induces Its Translocation in Rat Adipocytes Diabetes, October 1, 2001; 50(10): 2296 - 2300. [Abstract] [Full Text]

				B. Brunmair, F. Gras, S. Neschen, M. Roden, L. Wagner, W. Waldhausl, and C. Furnsinn Direct Thiazolidinedione Action on Isolated Rat Skeletal Muscle Fuel Handling Is Independent of Peroxisome Proliferator-Activated Receptor-{gamma}-Mediated Changes in Gene Expression Diabetes, October 1, 2001; 50(10): 2309 - 2315. [Abstract] [Full Text]

				A. L. Hevener, D. Reichart, A. Janez, and J. Olefsky Thiazolidinedione Treatment Prevents Free Fatty Acid-Induced Insulin Resistance in Male Wistar Rats Diabetes, October 1, 2001; 50(10): 2316 - 2322. [Abstract] [Full Text]

				Y. Miyazaki, A. Mahankali, M. Matsuda, L. Glass, S. Mahankali, E. Ferrannini, K. Cusi, L. J. Mandarino, and R. A. DeFronzo Improved Glycemic Control and Enhanced Insulin Sensitivity in Type 2 Diabetic Subjects Treated With Pioglitazone Diabetes Care, April 1, 2001; 24(4): 710 - 719. [Abstract] [Full Text]

				I. Gabriely, R. Wozniak, M. Hawkins, and H. Shamoon Troglitazone Amplifies Counterregulatory Responses to Hypoglycemia in Nondiabetic Subjects J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 521 - 528. [Abstract] [Full Text]

				S. D Clarke, P. Thuillier, R. A Baillie, and X. Sha Peroxisome proliferator-activated receptors: a family of lipid-activated transcription factors Am. J. Clinical Nutrition, October 1, 1999; 70(4): 566 - 571. [Abstract] [Full Text] [PDF]

				P. R. Shepherd and B. B. Kahn Glucose Transporters and Insulin Action -- Implications for Insulin Resistance and Diabetes Mellitus N. Engl. J. Med., July 22, 1999; 341(4): 248 - 257. [Full Text] [PDF]

				J. R. Zierath, J. W. Ryder, T. Doebber, J. Woods, M. Wu, J. Ventre, Z. Li, C. McCrary, J. Berger, B. Zhang, et al. Role of Skeletal Muscle in Thiazolidinedione Insulin Sensitizer (PPAR{gamma} Agonist) Action Endocrinology, December 1, 1998; 139(12): 5034 - 5041. [Abstract] [Full Text] [PDF]

				K. S. Park, T. P. Ciaraldi, L. Abrams-Carter, S. Mudaliar, S. E. Nikoulina, and R. R. Henry Troglitazone Regulation of Glucose Metabolism in Human Skeletal Muscle Cultures from Obese Type II Diabetic Subjects J. Clin. Endocrinol. Metab., May 1, 1998; 83(5): 1636 - 1643. [Abstract] [Full Text]